MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53
about
p38 phosphorylates Rb on Ser567 by a novel, cell cycle-independent mechanism that triggers Rb-Hdm2 interaction and apoptosisSUMOylation of hnRNP-K is required for p53-mediated cell-cycle arrest in response to DNA damageAnother fork in the road--life or death decisions by the tumour suppressor p53Functional Significance of Aurora Kinases-p53 Protein Family Interactions in CancerMolecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple MyelomaMithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma CellsTargeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myelomap53 modulation as a therapeutic strategy in gastrointestinal stromal tumorsIncreased expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53.Role of multi-hnRNP nuclear complex in regulation of tumor suppressor ANXA7 in prostate cancer cells.DC - SIGNR by influencing the lncRNA HNRNPKP2 upregulates the expression of CXCR4 in gastric cancer liver metastasis.The regulation of the p53-mediated stress response by MDM2 and MDM4.RITA displays anti-tumor activity in medulloblastomas independent of TP53 status.Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia.Integrated high-throughput analysis identifies Sp1 as a crucial determinant of p53-mediated apoptosis.The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias.Cardiovascular importance of the microRNA-23/27/24 family.p53 Family and Cellular Stress Responses in Cancer.Targeting p53 by small molecules in hematological malignancies.Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1Recent advances in p53 research and cancer treatmentWild type p53 reactivation: from lab bench to clinic.Non-coding RNAs and HIV: viral manipulation of host dark matter to shape the cellular environment.The p53-reactivating small molecule RITA induces senescence in head and neck cancer cellsDifferential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma.miR-24-2 controls H2AFX expression regardless of gene copy number alteration and induces apoptosis by targeting antiapoptotic gene BCL-2: a potential for therapeutic intervention.Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: targeting Warburg effect to fight cancer.Cytoplasmic Accumulation of Heterogeneous Nuclear Ribonucleoprotein K Strongly Promotes Tumor Invasion in Renal Cell Carcinoma Cells.hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies.A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.MDM4/HIPK2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage responsep53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?NuMA is required for the selective induction of p53 target genes.Integration of TP53, DREAM, MMB-FOXM1 and RB-E2F target gene analyses identifies cell cycle gene regulatory networks.ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis.MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.p53-based cancer therapyThe p53 target Wig-1: a regulator of mRNA stability and stem cell fate?p53-targeted cancer pharmacotherapy: move towards small molecule compounds.Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy.
P2860
Q24301099-843C9DEE-9FB0-44B3-90A3-D14B5B32CCA6Q24301634-4EA3A15E-0700-465B-BC0D-E2ABC1B43B2DQ27026310-692DB2EC-5351-49D1-B900-4B74D0F0010AQ28071615-FF7745CA-037E-42FF-8168-D99CE670956FQ28074490-37EDC8C2-6F31-4505-8ED6-306A41F22425Q28388640-FCDCE73D-EAFD-435F-BCA9-9CD8C4FF6DD5Q28479002-E8F4AE5F-EE8F-4A21-8ECD-665FACBC47F9Q28483922-D549530E-3851-40A0-B1B9-5569EAA1C500Q30492386-07188820-0046-4926-BAA2-9524F05C3E08Q33535225-94802C3B-3809-4B20-AAB0-D6DC82B49216Q33560349-01E3D8A5-98EC-4D47-B435-6524EDF2D045Q33685413-BF41AD62-6AC8-43D9-9C57-458CEE88703DQ33709483-5FD43EC7-5133-4CD8-91C9-083ED76A6C1FQ33997232-0D4F5D80-3CAA-4CC3-825A-5B737E5463FEQ34038417-B790807E-82CB-4ABF-B5DE-768B47E0E639Q34171407-F5ED7E72-A088-4601-B863-3FB47DBB567DQ34237674-F9867959-6D31-4CC9-9C4B-693CE788E33FQ34377287-484E055C-13DC-4F6E-8D03-44932593E272Q34636996-B3049D4F-500F-40BD-8DF4-0267AAC5DBD6Q35064994-327CF795-C7FE-48C3-8789-861F92A24312Q35099531-33E9F94A-770C-4D16-B7CF-5F11997C0077Q35146343-DA230225-119B-48B8-9AF5-4DF8C4DBFB11Q35219072-29290B66-2C88-4004-989F-546D5C61DD8AQ35224002-7B98086A-B9D0-4544-91F5-89C5691870CBQ35290386-C5DCD92D-5A11-41D9-8C80-D72D94B19057Q35559007-0E38908D-88CA-4121-AF4A-8002CECD03F7Q35842210-40BB0F80-E7B1-4EA1-BEEE-A94E760D9780Q35880529-859F9EA7-3DF9-4C6B-B2EF-208B175C7B27Q36298736-5A32F610-0EFB-4650-94BE-3F0B14EA15C1Q36338365-B2ECEC34-3381-4B7E-BB7E-5AE70777599EQ36474852-F411FB9B-0015-40DA-A64D-1A73E6F313D5Q36507052-0AB05869-2196-4321-B20B-BAD055F5E78CQ36978256-856E754E-0A9C-4B86-BEC8-0DDA26E38FFBQ37197461-DDF620F7-0D87-43AF-B80D-20F4152BEF5EQ37631181-00DA251B-CE63-4358-820A-43D40543350BQ37635027-3B3A181B-D944-4897-BDCB-669F7B303B11Q37750115-D7777047-9D90-4F14-AC90-4BA402458604Q37851826-9DA98E5B-09E9-4675-A638-C87423AC4E59Q37865050-A4BB7A40-065B-4A36-B5CD-909E4935D3DEQ38059739-64F8BB38-F686-4576-A578-2737482B899F
P2860
MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
MDM2-dependent downregulation ...... harmacologically activated p53
@ast
MDM2-dependent downregulation ...... harmacologically activated p53
@en
MDM2-dependent downregulation ...... harmacologically activated p53
@en-gb
MDM2-dependent downregulation ...... harmacologically activated p53
@nl
type
label
MDM2-dependent downregulation ...... harmacologically activated p53
@ast
MDM2-dependent downregulation ...... harmacologically activated p53
@en
MDM2-dependent downregulation ...... harmacologically activated p53
@en-gb
MDM2-dependent downregulation ...... harmacologically activated p53
@nl
prefLabel
MDM2-dependent downregulation ...... harmacologically activated p53
@ast
MDM2-dependent downregulation ...... harmacologically activated p53
@en
MDM2-dependent downregulation ...... harmacologically activated p53
@en-gb
MDM2-dependent downregulation ...... harmacologically activated p53
@nl
P2093
P50
P3181
P1433
P1476
MDM2-dependent downregulation ...... harmacologically activated p53
@en
P2093
Abdeladim Moumen
Elisabeth Hedström
Wenjie Bao
P304
P3181
P356
10.1016/J.CCR.2009.01.019
P407
P577
2009-03-01T00:00:00Z